Estropipate
Ogen, Ortho-est (estropipate) is a small molecule pharmaceutical. Estropipate was first approved as Ogen 5 on 1982-01-01. It is used to treat hot flashes, hypogonadism, menopause, menorrhagia, and premature menopause amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| endocrine system diseases | D004700 |
| signs and symptoms pathological conditions | D013568 |
| reproductive and urinary physiological phenomena | D012101 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| estropipate | ANDA | 2012-03-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hot flashes | — | D019584 | — |
| hypogonadism | HP_0000815 | D007006 | E23.0 |
| menopause | EFO_0003922 | D008593 | N95 |
| menorrhagia | HP_0000132 | D008595 | N92.0 |
| premature menopause | HP_0008209 | D008594 | E28.31 |
| primary ovarian insufficiency | EFO_0004266 | D016649 | E28.3 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
84 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menopause | D008593 | EFO_0003922 | N95 | 4 | 5 | 2 | 5 | 1 | 17 |
| Hot flashes | D019584 | — | — | 2 | 1 | 2 | 5 | ||
| Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | 1 | 3 | 1 | 5 | |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | 2 | 2 | 4 |
| Atrophic vaginitis | D059268 | EFO_1001271 | 2 | — | — | 2 | — | 4 | |
| Endometrial hyperplasia | D004714 | N85.0 | — | — | 2 | 1 | — | 3 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | 1 | — | 2 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | 1 | 1 | 2 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | 1 | 1 | — | 2 |
| Pelvic floor disorders | D059952 | — | — | — | 2 | — | 2 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 3 | 2 | — | 1 | 8 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | 4 | — | 1 | 5 |
| Hormone replacement therapy | D020249 | EFO_0003961 | Z79.890 | — | — | 1 | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | — | 1 |
| Coronary disease | D003327 | — | — | 1 | — | — | 1 | ||
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postmenopause | D017698 | 8 | 4 | — | — | 2 | 14 | ||
| Risk reduction behavior | D040242 | — | 1 | — | — | — | 1 | ||
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | G31.84 | — | 1 | — | — | — | 1 | |
| Ductal carcinoma breast | D018270 | — | 1 | — | — | — | 1 | ||
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | — | 1 |
| Prehypertension | D058246 | — | 1 | — | — | — | 1 | ||
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | 1 | — | — | — | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 1 | — | — | — | 1 | 2 |
| Estrogen replacement therapy | D015914 | 2 | — | — | — | — | 2 | ||
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | 1 | — | — | — | — | 1 | |
| Metrorrhagia | D008796 | HP_0100608 | N92.1 | 1 | — | — | — | — | 1 |
| Vaginitis | D014627 | EFO_0005757 | N76 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ESTROPIPATE |
| INN | — |
| Description | Estropipate is a steroid sulfate and a piperazinium salt. It is functionally related to an estrone. |
| Classification | Small molecule |
| Drug class | estrogens; atropine derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C1CNCCN1.C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O |
Identifiers
| PDB | — |
| CAS-ID | 7280-37-7 |
| RxCUI | 33747 |
| ChEMBL ID | CHEMBL1200980 |
| ChEBI ID | — |
| PubChem CID | 5284555 |
| DrugBank | DB04574 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 60 documents
View more details
Safety
Black-box Warning
Black-box warning for: Estropipate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
55,013 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more